sodium zirconium cyclosilicate

Sodium zirconium cyclosilicate is an inorganic, non-absorbed potassium binder used to treat hyperkalemia (high blood potassium) in adults. It acts by selectively capturing and exchanging potassium ions for sodium and hydrogen ions throughout the gastrointestinal tract, thereby reducing serum potassium levels and increasing fecal excretion of potassium. The compound is a microporous crystalline material composed of octahedrally coordinated zirconium and tetrahedrally coordinated silicon atoms, forming a cubic structure with pore sizes that mimic physiologic potassium channels. This selectivity allows it to entrap monovalent cations such as potassium and ammonium over divalent cations like calcium or magnesium. Sodium zirconium cyclosilicate is not systemically absorbed or metabolized; it remains in the GI tract until excreted in feces. Developed by AstraZeneca, it is marketed under the brand name Lokelma for oral administration as a powder for suspension[1][2][3][4][5][6][8].

Brand names

Lokelma

Other names

sodium zirconium silicateZS-9ZS9ZS 9